121 related articles for article (PubMed ID: 28218784)
1. Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes.
Zekri J; Al-Shehri A; Mahrous M; Al-Rehaily S; Darwish T; Bassi S; El Taani H; Al Zahrani A; Elsamany S; Al-Maghrabi J; Sadiq BB
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218784
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort.
Levi M; Prayogi G; Sastranagara F; Sudianto E; Widjajahakim G; Gani W; Mahanadi A; Agnes J; Khairunisa BH; Utomo AR
J Gastrointest Cancer; 2018 Jun; 49(2):124-131. PubMed ID: 28044264
[TBL] [Abstract][Full Text] [Related]
3. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia.
Zahrani A; Kandil M; Badar T; Abdelsalam M; Al-Faiar A; Ismail A
Tumori; 2014; 100(1):75-9. PubMed ID: 24675495
[TBL] [Abstract][Full Text] [Related]
4. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
5. Modified mismatch polymerase chain reaction-restriction fragment length polymorphism detected mutations in codon 12 and 13 of exon 2 of K-
Faleel FD; Zoysa MI; Lokuhetti MD; Gunawardena YI; Chandrasekharan VN; Dassanayake RS
J Cancer Res Ther; 2016; 12(4):1272-1277. PubMed ID: 28169239
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
7. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.
Renaud S; Guerrera F; Seitlinger J; Costardi L; Schaeffer M; Romain B; Mossetti C; Claire-Voegeli A; Filosso PL; Legrain M; Ruffini E; Falcoz PE; Oliaro A; Massard G
Oncotarget; 2017 Jan; 8(2):2514-2524. PubMed ID: 27911859
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
9. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
10. The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer: A National Study.
Cárdenas-Ramos SG; Alcázar-González G; Reyes-Cortés LM; Torres-Grimaldo AA; Calderón-Garcidueñas AL; Morales-Casas J; Flores-Sánchez P; De León-Escobedo R; Gómez-Díaz A; Moreno-Bringas C; Sánchez-Guillén J; Ramos-Salazar P; González-de León C; Barrera-Saldaña HA
Am J Clin Oncol; 2017 Jun; 40(3):274-276. PubMed ID: 25333735
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.
Veldore VH; Rao MR; Prabhudesai SA; Tejaswi R; Kakara S; Pattanayak S; Krishnamoorthy N; Tejaswini BN; Hazarika D; Gangoli A; Rahman SM; Dixit J; Naik R; Diwakar RB; Satheesh CT; Shashidhara HP; Patil S; Gopinath KS; Kumar BS
Indian J Cancer; 2014; 51(4):531-7. PubMed ID: 26842186
[TBL] [Abstract][Full Text] [Related]
12. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
14. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
[TBL] [Abstract][Full Text] [Related]
15. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.
Dadduzio V; Basso M; Rossi S; Cenci T; Capodimonti S; Strippoli A; Orlandi A; Cerchiaro E; Schinzari G; Cassano A; Martini M; Barone C
Mol Diagn Ther; 2016 Feb; 20(1):65-74. PubMed ID: 26610798
[TBL] [Abstract][Full Text] [Related]
16. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
18. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract][Full Text] [Related]
19. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
